

FROM
Intellectual Property Group of
Pillsbury Winthrop LLP
Attorneys at Law
P.O. Box 10500
McLean, VA 22102

Telephone: (703) 905-2000

Our Facsimile #: (703) 905-2500

FACSIMILE TRANSMISSION

TO: UNITED STATES PATENT AND TRADEMARK OFFICE

FACSIMILE #: (703) 872-9306

No. Pages (Including this page) 9

FAX Opr:

Arlenette
Footes

IF YOU DO NOT RECEIVE CLEARLY ALL PAGES, PLEASE CONTACT US IMMEDIATELY
By Telephone AT: (703)905-2200 (local)
or (703) 905-2000(local)

-->>>

USPTO:

PLEASE ACKNOWLEDGE CLEAR RECEIPT OF ALL PAGES INDICATED
ABOVE BY FAXING THIS PAGE BACK TO ONE OF OUR FACSIMILE
NUMBERS STATED ABOVE

In re PATENT APPLICATION of
Inventor(s) NOELLE et al.
Appl. No. 09/335,686

Group Art Unit: 1644
Examiner: P. Gambel

series code ↑ serial no.
Filed: June 18, 1999

Atty. Dkt. PM 0277164
M#

TITLE: Method for Prolonged
Suppression of Humoral Immune
Response to a Thymus-
Dependent Antigen Therapeutic
Agent

Date: October 25, 2002

Name or type of signed paper being transmitted:
Reply and Amendment Pursuant to 37 C.F.R. 1.111

MESSAGE:

BEST AVAILABLE COPY

(ATTN: Atty/Sec.: Transmit only one paper herewith. For papers not acceptable by fax, see back side or LAN
Form3 Directory PAT-286 Rear. Do not file originals but fasten them in our file (left side) with
this sheet and fax receipt on top. Do NOT send the originals nor a confirmation copy to the PTO.)

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent
and Trademark Office on the date shown below.

Name Robin L. Teskin Sig. [Signature] Date October 25, 2002

037003/0277164

PAT-286 7/99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): NOELLE et al.
 Appn. No. 09 335,686
 Series Code \uparrow Serial No. \uparrow

Group Art Unit 1644
 Examiner: P. Gambel
 Atty. Dkt P 0277164 1993-30-0090CP1C1
 MS Client Ref

Filed: June 18, 1999
 Hon. Commissioner of Patents
 Washington, D.C. 20231
 Sir:

Appln. Title: METHOD FOR PROLONGED
 SUPPRESSION OF HUMORAL IMMUNE
 RESPONSE TO A THYMUS-DEPENDENT
 ANTIGEN THERAPEUTIC AGENT

Date: October 25, 2002

REPLY/AMENDMENT/LETTER

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entry claim		Claims remaining after amendment	Highest number previously paid for	Present Extra	Larger/Small Entry	Additional Fee	Fee Code Lg/Sm
A. <input checked="" type="checkbox"/> NOT made	B. <input type="checkbox"/> Withdrawn						
For B & C See Required Separate Paper (Pat-256)							
			minus 0	0	x \$18/\$9 =	+ \$0	103/203
			minus 0	0	x \$84/\$42 =	+ \$0	102/202
2. Total Effective Claims							
3. Independent Claims							
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)				add	+ \$280/\$140 =	+ \$0	104/204
5. Original due Date: October 25, 2002			<input type="checkbox"/> NONE				
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached			(1 mo)	\$110/\$55 =	+ \$0		115/215
			(2 mos)	\$400/\$200 =			116/216
			(3 mos)	\$920/\$460 =			117/217
			(4 mos)	\$1,440/\$720 =			118/218
			(5 mos)	\$1,960/\$980 =			128/228
7. Enter any previous extension fee paid since above original due date and subtract					- \$0		
8. Extension Fee					+ \$0		
9. If Terminal Disclaimer attached, add Rule 20(d) official fee					+ \$110/\$55	+ \$0	148/248
10. If IDS attached requires Official Fee under Rule 97 (c), add					+ \$180	+ \$0	126
or if Rule 97(d) Request add					+ \$180	+ \$0	126
11. After-Final Request Fee per rules 129(a) and 17(r)					+ \$740/370	+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b)					x \$740/370 ea	+ \$0	149/249
13. Request for Continued Examination (RCE)					+ \$740/370	+ \$0	1179/1279
14. Petition fee for					+ \$0		
TOTAL FEE =						\$0	

15

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0"
 17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.
 18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space

Our Deposit Account No. 03-3975)

(Our Order No. 037003 0277164

Cs

MS

CHARGE STATEMENT. The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

P.O. Box 10500
 McLean, VA 22102
 Tel: (703) 905-2000

Pillsbury Winthrop LLP
 Intellectual Property Group

By Atty: Robin L. Teskin

Sig:

Reg. No. 35,030

Fax: (703) 905-2500

Tel: (703) 905-2200

Atty/Sec: RLT/af

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

BEST AVAILABLE COPY

PAT-120 5/02

#19/D
gnd
10/31/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

NOELLE et al.

Group Art Unit: 1644

Appln. No.: 09/335,686

Examiner: P. Gambel

Filed: June 18, 1999

Title: METHOD FOR PROLONGED SUPPRESSION OF HUMORAL IMMUNE RESPONSE
TO A THYMUS-DEPENDENT ANTIGEN THERAPEUTIC AGENT

October 25, 2002

* * * * *

REPLY AND AMENDMENT
PURSANT TO 37 C.F.R. §1.111Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated July 20, 2002, please amend the above-identified application as follows:

IN THE CLAIMS:

Kindly amend claim 44 as set forth below:

44. (Three Times Amended) A method for inducing prolonged humoral suppression in a subject in need of such prolonged humoral immune suppression, to a soluble thymus dependent (TD) antigen which method comprises:

(i) administering a soluble TD antigen to which a humoral response is to be suppressed; and

(ii) administering an amount of an anti-gp39 antibody or a fragment thereof that binds gp39, in an amount effective to provide for prolonged humoral immune suppression to said soluble TD antigen, wherein administration of (i) and (ii) is effected concurrently, and wherein prolonged humoral immune suppression means that suppression of antibody production against said TD antigen is maintained after administration of a gp39 antagonist, wherein said gp39 antagonist is an anti-gp39 antibody in vivo, has been terminated.

REMARKS

Entry of the foregoing amendments, reconsideration and re-examination of the subject application, as amended pursuant to and consistent with 37 C.F.R. §1.112, and in light of the remarks which follow are respectfully requested.